|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||2.45 - 2.64|
|52 Week Range||1.96 - 3.55|
|PE Ratio (TTM)||5.18|
|Earnings Date||Feb 21, 2018 - Feb 28, 2018|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||3.00|
PDL BioPharma Inc (NASDAQ:PDLI) trades with a trailing P/E of 5x, which is lower than the industry average of 28.5x. Although some investors may jump to the conclusion that thisRead More...
DALLAS and FORT WORTH, Texas , Feb. 20, 2018 /PRNewswire/ -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release ...
-- PDL does not plan to make any further proposals to acquire Neos -- INCLINE VILLAGE, Nev. , Feb. 20, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) today officially announced it will no longer ...
INCLINE VILLAGE, Nev. , Feb. 14, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , PDL's chief executive officer, will present at the following two ...
You'll probably be surprised by some of the stock picks from a leading artificial-intelligence system.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to PDL BioPharma, Inc. Here are 5 ETFs with the largest exposure to PDLI-US. Comparing the performance and risk of PDL BioPharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis PDL BioPharma, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of PDL BioPharma, Inc. – Compugen Ltd., Nektar Therapeutics, BioTime, Inc., Mylan N.V., Amgen Inc., Eli Lilly and Company and Sangamo Therapeutics, Inc. (CGEN-US, NKTR-US, BTX-US, MYL-US, AMGN-US, LLY-US ... Read more (Read more...)
DUBLIN , Nov. 15, 2017 /PRNewswire/ -- Noden Pharma DAC, a global specialty pharmaceutical company that is focused on acquiring prescription medicines across a broad range of therapeutic areas, announced ...
AstraZeneca (AZN) received CHMP recommendation for marketing approval of its pipeline candidate, benralizumab for treating severe eosinophilic asthma.
INCLINE VILLAGE, Nev., Nov. 8, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDLI) reiterated that its proposal to acquire Neos Therapeutics, Inc. (NEOS) for $10.25 per share in cash will expire today at market close. PDL originally made public its proposal to acquire Neos on October 26, 2017 at a premium of approximately 40 percent to the pre-proposal closing price of Neos shares. PDL is confident its proposal represents fair value for the Company and offers certain and compelling value for Neos shareholders.
INCLINE VILLAGE, Nev. , Nov. 7, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , PDL's president and chief executive officer, will present at two ...
The Incline Village, Nevada-based company said it had profit of 14 cents per share. Earnings, adjusted for one-time gains and costs, came to 15 cents per share. The biotechnology company posted revenue ...
NEW YORK, NY / ACCESSWIRE / November 2, 2017 / PDL BioPharma, Inc. (NASDAQ: PDLI ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 2, 2017 at 4:30 PM Eastern ...
U.S. drugmaker Neos Therapeutics Inc , which this week rejected a fourth takeover offer by PDL Biopharma Inc, will consider offers from other potential buyers, according to people familiar with the matter. Neos, a developer of attention deficit disorder treatments, rejected, as inadequate, a nearly $300 million all-cash bid from PDL that was more than a 40 percent premium to its market value. PDL could clinch a deal if it were to offer a higher price, the sources added, cautioning that there was no certainty of any transaction.
INCLINE VILLAGE, Nev. , Oct. 30, 2017 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today issued the following statement in response to the Neos Therapeutics, ...
DALLAS and FORT WORTH, Texas, Oct. 30, 2017 /PRNewswire/ -- Neos Therapeutics, Inc. (NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technologies, today announced that its Board of Directors has unanimously rejected the October 26 unsolicited proposal from PDL BioPharma, Inc. (PDLI) to acquire all of the outstanding shares of Neos for $10.25 per share in cash. Neos noted that PDL's October proposal is identical in all material respects to proposals received in June, July and September from PDL, which were also reviewed and unanimously rejected by the Neos Board. After a comprehensive review, conducted in consultation with its financial and legal advisors, the Neos Board affirmed its previous determinations that PDL's proposal undervalues Neos, does not reflect Neos' strategic value and future prospects for continued growth and value creation, and is not in the best interests of the Company or Neos shareholders.